🇺🇸 FDA
Patent

US 11401507

Remnant tumor infiltrating lymphocytes and methods of preparing and using the same

granted A61KA61K31/661A61K35/17

Quick answer

US patent 11401507 (Remnant tumor infiltrating lymphocytes and methods of preparing and using the same) held by Iovance Biotherapeutics, Inc. expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Iovance Biotherapeutics, Inc.
Grant date
Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K31/661, A61K35/17, A61K38/2013, A61K40/11